Helena Rodbard from Endocrine & Metabolic Consultants: Studying Canagliflozin as a Potential Treatment for Type 1 Diabetes Patients

Video

While it is not yet approved for the treatment of patients with type 1 diabetes recent studies on canagliflozin have shown it could be an option for this patient population.

While it is not yet approved for the treatment of patients with type 1 diabetes recent studies on canagliflozin have shown it could be an option for this patient population.

Helena W. Rodbard, MD, of Endocrine & Metabolic Consultants in Maryland and a past president of the American College of Endocrinology and the American Association of Clinical Endocrinologists discussed this research during the American Diabetes Association's annual meeting in New Orleans. While the medication is available for patients with type 2 diabetes already Rodbard said the results of this study showed benefits for the other form of diabetes as well.

Related Videos
Noa Krugliak Cleveland, MD | Credit: University of Chicago
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Ali Rezaie, MD | Credit: X
Should We Reclassify Diabetes Subtypes?
Remo Panaccione, MD | Credit: University of Calgary
Francisca Joly, MD, PhD | Credit: The Transplantation Society
Primary Care Roles in Alzheimer Diagnosis, with Theresa Sivers-Teixeira, MSPA, PA-C
Heart Failure Treatment Outcomes and Contraindications
Getting Black Men Involved in Their Health Care, Clinical Research
Patient Involvement in Advanced HF Treatment, with Ashley Malliett, DMSc, MPAS, PA-C
© 2024 MJH Life Sciences

All rights reserved.